Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Legislative Update — Week of May 6, 2024

  • Post author:PacConAdmin
  • Post published:May 6, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

As the second session of the 118th Congress begins, FDAnews will track important pending legislation, thathas been acted on since Oct. 1, 2023 to keep you updated on laws andregulations…

Continue ReadingLegislative Update — Week of May 6, 2024

EMA Reflection Paper Tackles Real-World Data in Non-Interventional Studies

  • Post author:PacConAdmin
  • Post published:May 3, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

The overall quality of data and risk of potential bias in them should be top of the mind for European sponsors who want to employ real-word data (RWD) in non-interventional…

Continue ReadingEMA Reflection Paper Tackles Real-World Data in Non-Interventional Studies

CDER’s Offices of New Drugs, Transitional Services Unveil 2023 Annual Reports

  • Post author:PacConAdmin
  • Post published:May 3, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

The FDA’s CDER has released 2023 Annual Reports for its Offices of New Drugs (OND) and Translational Services (OTS), highlighting activities that span dozens of drug approvals and guidances from…

Continue ReadingCDER’s Offices of New Drugs, Transitional Services Unveil 2023 Annual Reports

Quick Notes: Drug Approvals — May 3, 2024

  • Post author:PacConAdmin
  • Post published:May 3, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

In this edition of Quick Notes are drug approvals to treat hemophilia B, rare genetic disorder WHIM, cervical cancer, cluster seizures in children with epilepsy and a new formulation of…

Continue ReadingQuick Notes: Drug Approvals — May 3, 2024

Regulatory Update — Week of April 29, 2024

  • Post author:PacConAdmin
  • Post published:May 3, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

This week, the FDA announced a Metabolic Drugs Advisory Committee meeting and a listening session on advisory committees. Draft guidances were published on content and format of NDA and ANDA…

Continue ReadingRegulatory Update — Week of April 29, 2024

ICER Researcher Raises Concern Over Possible FDA Full Approval of DMD Treatment

  • Post author:PacConAdmin
  • Post published:May 3, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

Using Sarepta’s treatment for Duchenne muscular dystrophy (DMD) as an example, a researcher from the Institute for Clinical Review (ICER) said in a recent article that the FDA should be…

Continue ReadingICER Researcher Raises Concern Over Possible FDA Full Approval of DMD Treatment

Skinny-Labeled Generics Saved Medicare Billions Over Six Years

  • Post author:PacConAdmin
  • Post published:May 2, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

“Skinny labeling” on 15 generic drugs saved Medicare an estimated $14.6 billion from 2015-2021, but patent lawsuits may threaten the practice, according to an analysis published in the Annals of…

Continue ReadingSkinny-Labeled Generics Saved Medicare Billions Over Six Years

Quick Notes: Device Clearances and Approvals — May 2, 2024

  • Post author:PacConAdmin
  • Post published:May 2, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

This edition of Quick Notes reviews the FDA’s approval of Medtronic’s closed-loop rechargeable spinal cord stimulator, Abbott’s below the knee Everolimus Eluting Resorbable Scaffold System, an integrated continuous glucose monitor,…

Continue ReadingQuick Notes: Device Clearances and Approvals — May 2, 2024

Head of FDA’s ORA Worried Budget Woes Could Lead to Fewer Inspections

  • Post author:PacConAdmin
  • Post published:May 2, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

Shouldering the cost of FY25 federal employee pay increases may cause the FDA’s Office of Regulatory Affairs (ORA) to reduce the number of inspections it can conduct, said the office’s…

Continue ReadingHead of FDA’s ORA Worried Budget Woes Could Lead to Fewer Inspections

Apple Watch AFib History Feature Qualified for Use in Medical Device Development

  • Post author:PacConAdmin
  • Post published:May 2, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

The Apple Watch’s atrial fibrillation (AFib) history feature is now qualified as the first digital health technology under the FDA’s Medical Device Development Tools (MDDT). Source: Drug Industry Daily

Continue ReadingApple Watch AFib History Feature Qualified for Use in Medical Device Development
  • Go to the previous page
  • 1
  • …
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • …
  • 328
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.